Last reviewed · How we verify
Placebo to zoledronic acid
Placebo to zoledronic acid is a Bisphosphonate Small molecule drug developed by Amgen. It is currently FDA-approved for Hypercalcemia of malignancy, Multiple myeloma with bone disease, Bone metastases from solid tumors.
Zoledronic acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
Zoledronic acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway. Used for Hypercalcemia of malignancy, Multiple myeloma with bone disease, Bone metastases from solid tumors.
At a glance
| Generic name | Placebo to zoledronic acid |
|---|---|
| Sponsor | Amgen |
| Drug class | Bisphosphonate |
| Target | Farnesyl pyrophosphate synthase; hydroxyapatite in bone |
| Modality | Small molecule |
| Therapeutic area | Oncology; Bone metabolism disorders |
| Phase | FDA-approved |
Mechanism of action
Zoledronic acid works by reducing osteoclast activity and promoting osteoclast apoptosis, thereby decreasing bone turnover and resorption. It is used to treat conditions characterized by excessive bone loss or abnormal bone metabolism, including osteoporosis, hypercalcemia of malignancy, and bone metastases. The drug strengthens bone density and reduces fracture risk by shifting the balance toward bone formation.
Approved indications
- Hypercalcemia of malignancy
- Multiple myeloma with bone disease
- Bone metastases from solid tumors
- Osteoporosis prevention and treatment
Common side effects
- Osteonecrosis of the jaw
- Atypical femoral fractures
- Renal impairment
- Hypocalcemia
- Fever and flu-like symptoms
- Arthralgia/myalgia
Key clinical trials
- Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea (PHASE3)
- Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults (PHASE2)
- Romosozumab Use to Build Skeletal Integrity (PHASE4)
- Preserving Geriatric Muscle With an Osteoporosis Medication (PHASE4)
- Prevention of Bone Loss After Acute SCI by Zoledronic Acid (PHASE2)
- Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery (PHASE4)
- Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2) (PHASE4)
- RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to zoledronic acid CI brief — competitive landscape report
- Placebo to zoledronic acid updates RSS · CI watch RSS
- Amgen portfolio CI
Frequently asked questions about Placebo to zoledronic acid
What is Placebo to zoledronic acid?
How does Placebo to zoledronic acid work?
What is Placebo to zoledronic acid used for?
Who makes Placebo to zoledronic acid?
What drug class is Placebo to zoledronic acid in?
What development phase is Placebo to zoledronic acid in?
What are the side effects of Placebo to zoledronic acid?
What does Placebo to zoledronic acid target?
Related
- Drug class: All Bisphosphonate drugs
- Target: All drugs targeting Farnesyl pyrophosphate synthase; hydroxyapatite in bone
- Manufacturer: Amgen — full pipeline
- Therapeutic area: All drugs in Oncology; Bone metabolism disorders
- Indication: Drugs for Hypercalcemia of malignancy
- Indication: Drugs for Multiple myeloma with bone disease
- Indication: Drugs for Bone metastases from solid tumors
- Compare: Placebo to zoledronic acid vs similar drugs
- Pricing: Placebo to zoledronic acid cost, discount & access